BMS Moves Closer To Subcutaneous Opdivo With Phase III Trial Success

 
• By Joseph Haas
  
Chemical process
Bristol makes progress in formulating a subcutaneous version of Opdivo • Source: Shutterstock

More from Immuno-oncology

More from Anticancer